MPMark Pakianathan

Mark Pakianathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Pakianathan has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing a coordinated response to chemsex across health, justice and social care settings: expert consensus statement

    by Bradley Hillier, Eliott Carthy, Nicola Kalk, Monty Moncrieff, Mark Pakianathan, Derek Tracy, Owen Bowden-Jones, Ford Hickson, Andrew Forrester

    Summary: Chemsex occurs primarily among gay, bisexual and other men who have sex with men (GBMSM), and there is evidence of a subgroup of users who carry out chemsex-related criminal offences and experience harm. Challenges with chemsex can present to various settings; there are concerns that harm is increasing, including at interfaces between health, social care and criminal justice systems. The UK response to date has lacked a coordinated approach. An expert reference group was convened to share chemsex knowledge, articulate priorities for research and pathway development, and foster collaborative working between agencies. It made three key recommendations: develop and increase training and awareness across all services; implement a coordinated research programme with the development of a common data-set and assessment tool to fully characterise population-level needs; develop a professional network to share information, provide professional support and act as a knowledge hub. There was support for a unified multi-agency strategy incorporating the priorities identified as overarching principles.


  • Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics

    by M Pakianathan, W Whittaker, Mj Lee, J Avery, S Green, B Nathan, A Hegazi

    Objectives: The aim of the study was to analyse associations between chemsex and new HIV and sexually transmitted infection (STI) diagnoses among gay, bisexual and other men who have sex with men (GBMSM) accessing sexual health clinics.Methods: A retrospective case note review was carried out for all GBMSM attending two London sexual health clinics between 1 June 2014 and 31 July 2015.Results: Chemsex status was documented for 1734 of 1840 patients. Overall, 27.1% (n = 463) disclosed current recreational drug use, of whom 286 (16.5%) disclosed chemsex participation and 74 of 409 (18.1%) injected drugs. GBMSM who were already HIV positive were more likely to disclose chemsex participation [adjusted odds ratio (AOR) 2.55; 95% confidence interval (CI) 1.89–3.44; P < 0.001]. Those disclosing chemsex participation had higher odds of being newly diagnosed with HIV infection (AOR 5.06; 95% CI 2.56–10.02; P < 0.001), acute bacterial STIs (AOR 3.94; 95% CI 3.00–5.17; P < 0.001), rectal STIs (AOR 4.45; 95% CI 3.37–6.06; P < 0.001) and hepatitis C (AOR 9.16; 95% CI 2.31–36.27; P = 0.002). HIV‐negative chemsex participants were also more likely to have accessed post‐exposure prophylaxis for HIV in the study period and to report sex with a discordant HIV‐ or hepatitis C virus‐infected partner (P < 0.001).Conclusions: Chemsex disclosure in sexual health settings is associated with higher rates of STI diagnoses, including HIV infection and hepatitis C. GBMSM attending sexual health services should therefore be assessed for chemsex participation and disclosure should prompt health promotion, harm minimization and wellbeing interventions.


  • Sharing solutions for a reasoned and evidence-based response: chemsex/party and play among gay and bisexual men

    by Adam Bourne, Jason Ong, Mark Pakianathan

    This Special Issue of Sexual Health examines research and healthcare practice relating to sexualised drug use among gay, bisexual and other men who have sex with men (GBMSM), colloquially known as ‘chemsex’ or ‘party and play’ (PnP). It draws together evidence relating to the epidemiology, sociology and psychology of chemsex, as well as the policy, community and clinical interventions that are required to ensure men have access to high-quality health care that meets their needs and reduces harm. Findings and discussions within the Issue emphasise the need to sensitively, non-judgementally and meaningfully engage with gay men about their engagement in chemsex in order to help improve their sexual health and wider wellbeing.


  • LGBT sexual health

    by Aseel Hegazi, Mark Pakianathan


  • Gay, bisexual, and other men who have sex with men: time to end the fixation with HIV

    by M Pakianathan, N Daley, A Hegazi

    Attention must shift to broader inequalities in health and wellbeing HIV has been inextricably linked with gay men’s health since the term “gay related immune deficiency” was first used to refer to AIDS in the early 1980s. Today, the collective emphasis of health interventions targeted at gay, bisexual, and other men who have sex with men remains focused on preventing sexually transmitted infection, to the extent that absence of HIV has come to be regarded almost synonymously with gay men’s health. Beyond HIV, health disparities in this group of men encompass a range of physical conditions, including asthma, cardiovascular disease, and cancer.1 They are also more likely to experience physical disability and to report poorer self rated health.1 Determinants of these differences have received limited public and medical attention and remain relatively unstudied. Further inequality is driven by an unwillingness to seek medical care or disclose sexuality to healthcare providers because of perceived negative healthcare experiences.2 Demographic and socioeconomic factors also contribute independently to health disparities within this diverse population.3 …


  • Top Cited Papers

    Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics

    by A Hegazi, Mj Lee, W Whittaker, S Green, R Simms, R Cutts, M Nagington, B Nathan, M R Pakianathan

    The objective of this study was to analyse associations between sexualised substance use (chemsex), STI diagnoses and sexual behaviour among gay bisexual and other men who have sex with men accessing sexual health clinics to better inform clinical pathways. A retrospective case notes review was undertaken following the introduction of more detailed and holistic profomas for all gay bisexual and other men who have sex with men attending two London sexual health clinics between 1 June 2014 and 31 January 2015. Chemsex status was documented for 655/818. Overall, 30% disclosed recreational drug use of whom 113 (57%) disclosed chemsex and 27 (13.5%) injecting drugs. HIV-positive gay bisexual and other men who have sex with men were more likely to disclose chemsex (AOR 6.68; 95% CI 3.91–11.42; p < 0.001). Those disclosing chemsex had a higher incidence of acute bacterial STIs (AOR 2.83 CI 1.79–4.47; p < 0.001), rectal STIs (AOR 3.10 CI 1.81–5.32; p < 0.001) or hepatitis C (AOR 15.41 CI 1.50–158.17; p = 0.021). HIV incidence in the study period was 1.8% (chemsex) vs. 0.9% (no chemsex) (p = 0.61). Chemsex was associated with having more sexual partners, transactional sex, group sex, fisting, sharing sex toys, injecting drug use, higher alcohol consumption and the use of ‘bareback’ sexual networking applications (p < 0.004). Chemsex participants were also more likely to have accessed post-exposure prophylaxis for HIV in the study period and report sex with a discordant HIV or hepatitis C-infected partner (p < 0.001). Chemsex disclosure is associated with higher risk-taking behaviours, acute bacterial STIs, rectal STIs and hepatitis C incidence. HIV incidence was higher but not significantly so in the study period. Chemsex disclosure in sexual health clinics should prompt an opportunity for prevention, health promotion and wellbeing interventions.


  • How to assess gay, bisexual and other men who have sex with men for chemsex

    by M R Pakianathan, M J Lee, B Kelly, A Hegazi

    Objectives Sexualised substance use, ‘chemsex’, is being increasingly reported by gay, bisexual and other men who have sex with men (GBMSM) in sexual health clinics. We aim to describe the evidence base and practical ways in which clinicians can assess and advise patients disclosing chemsex. Methods We review published literature on chemsex, discuss vulnerability to substance use, highlight the importance of clinical communication and discuss a management approach. Results GBMSM are vulnerable to substance use problems, which interplay with mental, physical and sexual health. Knowledge on sexualised drug use and related communication skills are essential to facilitating disclosure. Identifying sexual health and other consequences of harmful drug use may motivate patients to seek change. Conclusions Sexual health clinicians are well placed to make more holistic assessments of GBMSM accessing their services to promote broader sexual health and well-being beyond the management of HIV and sexually transmitted infections (STIs) alone.


  • Open Access

    Increasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention

    by Claire L. McCormick, Arianne M. Francis, Kim Iliffe, Helen Webb, Catherine J. Douch, Mark Pakianathan, Derek C. Macallan

    Objectives To investigate changing nutritional demographics of treated HIV-1-infected patients and explore causes of obesity, particularly in women of African origin. Methods We prospectively reviewed nutritional demographics of clinic attenders at an urban European HIV clinic during four one-month periods at 3-yearly intervals (2001, 2004, 2007, and 2010) and in two consecutive whole-year reviews (2010-11 and 2011-12). Risk-factors for obesity were assessed by multiple linear regression. A sub-study of 50 HIV-positive African female patients investigated body-size/shape perception using numerical, verbal and pictorial cues. Results We found a dramatic rise in the prevalence of obesity (BMI >30 kg/m2), from 8.5% (2001) to 28% (2011-12) for all clinic attenders, of whom 86% were on antiretroviral treatment. Women of African origin were most affected, 49% being obese, with a further 32% overweight (BMI 25-30 kg/m2), in 2012. Clinical factors strongly associated with obesity included female gender, black African ethnicity, non-smoking, age and CD4 count (all P<0.001); greater duration of cART did not predict obesity. Individual weight-time trends mostly showed slow long-term progressive weight gain. Investigating body weight perception, we found that weight and adiposity were underestimated by obese subjects, who showed a greater disparity between perceived and actual adiposity (P<0.001). Obese subjects targeted more obese target “ideal” body shapes (P<0.01), but were less satisfied with their body shape overall (P=0.02). Conclusions Seropositive African women on antiretroviral treatment are at heightened risk of obesity. Although multifactorial, bodyweight perception represents a potential target for intervention.